

2016-2017 Strategic Plan Objectives

Question 1: How Can I Recognize the Signs of ASD, and Why is Early Detection So Important?

- 1.1.** Strengthen the evidence base for the benefits of early detection of ASD.
- 1.2.** Reduce disparities in early detection and access to services
- 1.3.** Improve/validate existing, or develop new tools, methods, and service delivery models for detecting ASD in order to facilitate timely linkage of individuals with ASD to early, targeted interventions and supports.

Question 2: What Is the Biology Underlying ASD?

- 2.1.** Foster research to better understand the processes of early development, molecular, and neurodevelopmental mechanisms, and brain circuitry that contribute to the structural and functional basis of ASD.
- 2.2.** Support research to understand the underlying biology of co-occurring conditions in ASD and to understand the relationship of these conditions to ASD.
- 2.3.** Support large scale longitudinal studies that can answer questions about the development of ASD from pregnancy through adulthood and the natural history of ASD across the lifespan.

Question 3: What Causes ASD, and Can Disabling Aspects of ASD be Prevented or Preempted?

- 3.1.** Strengthen understanding of genetic risk and resilience factors for ASD across the full diversity and heterogeneity of those with ASD, enabling development of strategies for reducing disability and co-occurring conditions in ASD.
- 3.2.** Understand the effects on ASD risk and resilience of individual and multiple exposures in early development, enabling development of strategies for reducing disability and co-occurring conditions in ASD.
- 3.3.** Expand knowledge about how multiple environmental and genetic risk and resilience factors interact through specific biological mechanisms to manifest in ASD phenotypes.

Question 4: Which Treatments and Interventions Will Help?

- 4.1. Develop and improve pharmacological and medical interventions to address both core symptoms and co-occurring conditions in ASD.
- 4.2. Create and improve psychosocial, developmental, and naturalistic interventions for the core symptoms and co-occurring conditions in ASD.
- 4.3. Maximize the potential for technologies and development of technology-based interventions to improve the lives of people on the autism spectrum.

Question 5: What Kinds of Services and Supports are Needed to Maximize Quality of Life for People on the Autism Spectrum?

- 5.1. Scale up and implement evidence-based interventions in community settings.
- 5.2. Reduce disparities in access and in outcomes for underserved populations.
- 5.3. Improve service models to ensure consistency of care across many domains with the goal of maximizing outcomes and improving the value that individuals get from services.

Question 6: How Can We Meet the Needs of People With ASD As They Progress Into and Through Adulthood?

- 6.1. Support development and coordination of integrated services to help youth make a successful transition to adulthood and continue to provide supports throughout the lifespan.
- 6.2. Support research and implement approaches to reduce disabling co-occurring physical and mental health conditions in adults with ASD, with the goal of improving safety, reducing premature mortality, and enhancing quality of life.
- 6.3. Support research, services activities, and outreach efforts that facilitate and incorporate acceptance, accommodation, inclusion, independence, and integration of people on the autism spectrum into society.

Question 7: How Do We Continue to Build, Expand, and Enhance the Infrastructure System to Meet the Needs of the ASD Community?

7.1. Promote growth, integration, and coordination of the biorepository infrastructure.

7.2. Develop, enhance, and link the data repositories.

7.3. Expand and enhance the research and services workforce and accelerate the pipeline from research to practice.

7.4. Strengthen ASD surveillance systems to further understanding of the population of individuals with ASD, while allowing comparisons and linkages across systems as much as possible.

Burden Statement: Public reporting burden for this collection of information is estimated to average 15 gathering and maintaining the data needed, and completing and reviewing the collection of information. **collection of information unless it displays a currently valid OMB control number.** Send commen suggestions for reducing this burden, to: NIH, Project Clearance Branch, Rockledge I, 6705 Rockledge address.

* Please note that the use of the word 'response' in the Burden Statement refers to each individual proje

OMB# 0925-0682 Expiration: 1/31/2026

20XX ASD Research Spreadsheet

Organization Name
[FILL IN NAME]

20XX Total Funding	20

For previously funded projects, please consider a project Ongoing if it received funding or had active research at any time in 202X.

202X Project Number	202X Project Number	Project Status in 202X	Start Date (mm/dd/yyyy)
Enter all new 202X project information in the adjacent cells		New	
Enter all new 202X project information in the adjacent cells		New	

minutes per response*, including the time for reviewing instructions, searching existing data sources, **An agency may not conduct or sponsor, and a person is not required to respond to,** a ts regarding this burden estimate or any other aspect of this collection of information, including Drive, Bethesda, MD 20892-7983, ATTN: PRA (0925-0682*). Do not return the completed form to this

ect that is reported, and not the data call in its entirety.




XX Total Projects

End Date (mm/dd/yyyy)	Multi-site (Yes/No)	Principal Investigator (Last, First)	Project Title



Institution	State	Country	202X Funding	202X Funding





Please provide a Weblink/url to a project description. If a Weblink is unavailable, please provide a project description.

Previous Weblink to Project Description	Previous Project Description	New or Revised Weblink	New or Revised Project Description



Previous SP Question Code	Previous SP Objective Code	Suggested 202X PA Question Code (BY AGENCY/ORG)



Suggested 202X PA Objective Code (BY AGENCY/ORG)	Comments

If you are aware of additional projects funded by your organization that may address a broader information in the rows below. The funding for these projects will not be included in your orga publicly available in the IACC Portfolio Analysis Report.

202X Project Number	202X Project Number	Start Date (mm/dd/yyyy)	End Date (mm/dd/yyyy)
Enter all new 202X project information in the adjacent cells			

For scientific scope but still have relevance to autism, please provide organization's total for autism spending, but project details may be made

Principal Investigator	Project Title	Institution

State / Country	2019 Funding	Weblink

Project Description	Comments